

Mallinckrodt plc (MNK)

\$2.96 (As of 05/14/20)

Price Target (6-12 Months): **\$3.25**

Long Term: 6-12 Months

Zacks Recommendation:
Neutral

(Since: 04/29/19)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:A

Value: A

Growth: A

Momentum: C

Summary

Mallinckrodt's first-quarter results were disappointing, with earnings beating estimates but sales missing the same. Most products have registered a decline due to the ongoing pandemic and the impact will be magnified in the second quarter. The company warned that the next few quarters will be challenging due to the impact of COVID-19, as some of its products are sensitive to reduced numbers of surgical procedures and doctor visits. Meanwhile, the company is embroiled in a litigation with the U.S. Department of Health and Human Services and CMS related to the calculation of Medicaid drug rebates for Acthar. Its shares have underperformed the industry in the past year. Nevertheless, the pipeline progress has been encouraging with StrataGraft and terlipressin, and probable approvals should boost the top line.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$15.39 - \$1.00
20 Day Average Volume (sh)	5,583,829
Market Cap	\$250.0 M
YTD Price Change	-15.2%
Beta	3.57
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Generic Drugs
Zacks Industry Rank	Top 7% (18 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	16.3%
Last Sales Surprise	-2.2%
EPS F1 Est- 4 week change	-3.4%
Expected Report Date	08/04/2020
Earnings ESP	0.0%
P/E TTM	0.3
P/E F1	0.5
PEG F1	0.0
P/S TTM	0.1

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	570 E	602 E	590 E	604 E	2,398 E
2020	666 A	628 E	650 E	694 E	2,638 E
2019	791 A	823 A	744 A	805 A	3,163 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$0.73 E	\$0.94 E	\$0.81 E	\$1.07 E	\$4.09 E
2020	\$1.64 A	\$1.22 E	\$1.42 E	\$1.66 E	\$5.91 E
2019	\$1.94 A	\$2.53 A	\$2.07 A	\$2.40 A	\$8.88 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 05/14/2020. The reports text is as of 05/15/2020.


Overview

Dublin, Ireland-based Mallinckrodt is a specialty biopharmaceutical with a worldwide presence. The company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical and biopharmaceutical products and therapies as well as nuclear medicine products.

Mallinckrodt operates under two segments — Specialty Brands and Specialty Generics. Specialty Brands produces and markets branded pharmaceutical products, like Acthar and Ofirmev, and biopharmaceuticals. Specialty Generics produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic-controlled substances, acetaminophen and other active ingredients. In December 2018, the company announced that it intends to spin-off the Specialty Generics business into a new company. Mallinckrodt expects that Specialty Generics, which manufactures certain generic opioid products, among other products, will file voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the coming months. The settlement terms include structured payments of \$1.6 billion over eight years and warrants for 19.99% of company's outstanding shares.

Mallinckrodt's key acquisitions include Cadence Pharmaceuticals in March 2014, Questcor Pharmaceuticals in August 2014, Ikaria in April 2015, Therakos in September 2015 and three commercial-stage topical hemostasis drugs from The Medicines Company in February 2016. The company also acquired Sucampo in February 2018. Meanwhile, the company sold its contrast media and delivery systems (CMDs) business in November 2015. Mallinckrodt sold its Nuclear Imaging business to IBA Molecular and Intrathecal Therapy business to Piramal Enterprises Limited.

Net sales came in at \$3.16 billion in 2019.



Reasons To Buy:

▲ **Opioid Settlement A Relief:** Mallinckrodt recently announced that the company and its specialty generics-focused subsidiaries Mallinckrodt LLC and SpecGx LLC, and certain other affiliates have reached an agreement in principle on the terms of a global settlement that would resolve all opioid-related claims against the company, Specialty Generics and other subsidiaries. The agreement in principle has been reached with a court-appointed plaintiff's executive committee representing the interests of thousands of plaintiffs in the opioid multidistrict litigation, and is supported by a broad-based group of 47 states and U.S. Territory Attorneys General.

Inomax and Acthar hold significant potential. The company continues to work on boosting presence of these drugs in the hospital segment.

▲ **Untapped Potential in Acthar Gel:** Acthar Gel, which became part of the company's portfolio following the Questcor acquisition, continues to drive growth. Performance of the drug has been impressive aided by solid demand in rheumatology, pulmonology, ophthalmology and nephrology indications, and expanded access in more recently promoted indications such as lupus and sarcoidosis, and mature indications such as infantile spasms and nephrotic syndrome.

▲ **Strong Hospital Portfolio:** Mallinckrodt's hospital portfolio is now its largest and fastest growing platform in terms of sales. The acquisition of critical-care company, Ikaria added Inomax (a vasodilator used in conjunction with ventilatory support and other appropriate agents) to the company's portfolio. The acquisition broadened Mallinckrodt's footprint in hospitals and expanded its presence to include critical-care respiratory therapies in neonatal intensive care units. Growth continues to be driven by sustained, consistent demand and contract renewals fueled by the product's differentiated total service model.

Also, the Cadence acquisition added Ofirmev to the company's specialty pharmaceuticals portfolio, expanding its pain management franchise. With Ofirmev, Mallinckrodt targets the adjacent acute-care hospital market. Penetration rates on available surgical procedures are relatively low and hospitals continue to develop recovery standards after surgery protocols, which should drive the sale of products like Ofirmev and enable patients to recover quicker after surgery. Growth of the drug is expected to be driven by strong demand, as customers focus on non-opioid or multimodal pain management.

▲ **Promising Candidates in The Pipeline:** Mallinckrodt is striving hard to diversify its portfolio. Two late-phase programs — terlipressin and StrataGraft — in the pipeline promise potential. Patients are being enrolled in the ongoing phase III trial on pipeline candidate, terlipressin for the treatment of Hepatorenal Syndrome type 1. Mallinckrodt announced positive top-line results from its phase III CONFIRM study evaluating the efficacy and safety of terlipressin in 300 adults with hepatorenal syndrome type 1 (HRS-1). The study met its primary endpoint of verified HRS-1 reversal and the company has already submitted a New Drug Application to the FDA.

StrataGraft is in phase III development for the treatment of deep partial thickness burns and phase II development for full thickness burns. The company recently reported positive top-line results from its pivotal phase III study of StrataGraft regenerative tissue. The study, which met both primary endpoints, evaluated the efficacy and safety of a single application of the candidate for the treatment of deep partial-thickness thermal burns. Mallinckrodt recently initiated the rolling submission of a biologics license application (BLA) to the FDA for StrataGraft regenerative skin tissue, to treat adults with deep partial-thickness thermal burns.

Reasons To Sell:

▼ **Share Price Performance:** Mallinckrodt has underperformed the industry in the past year. The COVID-19 pandemic will adversely impact the company's business due to the stay-at-home orders, reduction of elective surgeries and a drop in overall patient procedures. The performance of Acthar gel, Therakos and Ofirmev will be more significant as these products are the most sensitive to the restrictions.

Pricing pressure in the generic segment and the rising menace of penalties regarding opioid litigations are a concern.

In March, the U.S. Attorney's office in Massachusetts announced its intervention in a lawsuit filed against the company alleging violations of the False Claims Act relating to the method to calculate Medicaid drug rebates for Acthar. Thereafter, the U.S. District Court for the District of Columbia ruled against Mallinckrodt in its lawsuit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services (CMS) regarding the company's calculation of Medicaid drug rebates for Acthar.

▼ **Pipeline Setbacks:** The company suffered a setback when the FDA's Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee recommended in a vote of 21 to 3 that the risk-benefit profile of stannosporfin does not support approval for the treatment of newborns aging 35 weeks or more of gestational age with indicators of hemolysis who are at risk of developing hyperbilirubinemia (severe jaundice). The FDA has issued a complete response letter to its new drug application (NDA) for stannosporfin. The letter provides guidance on areas of further evaluation for resubmitting the NDA. Similar setbacks will adversely impact the stock.

▼ **Acthar Under Pressure:** Acthar continues to face reimbursement pressures because payers challenge longer duration prescriptions for certain indications. Consequently, sales have been declining for the last few quarters. Competition is also increasing for Amitiza in the United States.

Last Earnings Report

Mallinckrodt Q1 Earnings Beat Estimates, Sales Miss

Mallinckrodt reported adjusted earnings of \$1.64 per share in the first quarter, beating the Zacks Consensus Estimate of \$1.41 but decreasing from the year-ago quarter's \$1.94.

Net sales in the quarter came in at \$665.8 million, decreasing 15.8% year over year and missing the Zacks Consensus Estimate of \$678 million.

Quarter Ending **03/2020**

Report Date	May 05, 2020
Sales Surprise	-2.15%
EPS Surprise	16.31%
Quarterly EPS	1.64
Annual EPS (TTM)	8.64

Quarter in Detail

The company now operates in two reportable segments aligned with the previously-announced separation — the Specialty Brands and the Specialty Generics.

Specialty Brands' sales came in at \$490.6 million, down 18.8% year over year.

Acthar, Mallinckrodt's largest product, generated sales of \$167.6 million, down 25.1% year on year, primarily due to continued reimbursement challenges affecting new and returning patients, continued payer scrutiny on overall specialty pharmaceutical spending, and reduced patient demand due to the COVID-19 stay-at-home order.

Inomax, the company's second-largest product, generated sales of \$141.7 million, down 6.2% year over year due to increased competition for inhaled nitric oxide.

Ofirmev sales decreased 21.7% year over year to \$74.9 million due to significant quarter-to-quarter order variability and a reduction in elective surgeries due to public health orders and institutions focusing on responding to the COVID-19 pandemic.

Sales of the Therakos immunology platform came in at \$63.7 million, up 3.1%.

Amitza net sales were \$41.1 million, down 22.5% due to increased competition in the United States and the biennial price reduction in Japan.

Specialty Generics' sales amounted to \$175.2 million, down 6%.

Adjusted selling, general and administrative expenses were \$187.2 million, down from the year-ago quarter's \$211.4 million. Research and development expenses decreased to \$77.4 million from \$85.3 million owing to the completion of two phase III clinical trials in late 2019.

Guidance

Reduced patient demand due to the COVID-19 stay-at-home order started affecting the business toward the end of the first quarter and the company expects this impact to be more significant in the second quarter at least.

Litigation Update

In February 2020, Mallinckrodt announced an agreement in principle for a global resolution to its opioid litigation, subject to certain conditions. The agreement in principle has been reached with a court-appointed plaintiff's executive committee representing the interests of thousands of plaintiffs in the opioid multidistrict litigation and is supported by a broad-based group of 47 states and U.S. Territory Attorneys General.

In March, the U.S. Attorney's office in Massachusetts announced its intervention in a lawsuit filed against the company alleging violations of the False Claims Act relating to the method to calculate Medicaid drug rebates for Acthar. Thereafter, the U.S. District Court for the District of Columbia ruled against Mallinckrodt in its lawsuit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services (CMS) regarding the company's calculation of Medicaid drug rebates for Acthar.

Recent News

Starts Rolling BLA Filing for StrataGraft Tissue - Apr 6

Mallinckrodt announced that it has initiated the rolling submission of a biologics license application (BLA) to the FDA for its investigational product, StrataGraft regenerative skin tissue, to treat adults with deep partial-thickness thermal burns.

The BLA is based on data from the pivotal phase III STRATA2016 clinical study with support from the STRATA2011 clinical study. The company expects to complete the BLA submission in the coming months.

If approved, StrataGraft skin tissue can be a potential new treatment option for the given patient population.

Completes Rolling Submission For Terlipressin - Mar 17

Mallinckrodt announced that it has completed the rolling submission of the new drug application ("NDA") seeking approval for its pipeline candidate, terlipressin, as a treatment for hepatorenal syndrome type 1 (HRS-1). The life-threatening syndrome involves acute kidney failure in cirrhosis patients. The company initiated the rolling submission last month. The company stated that the NDA submission is considered as a Class 2 resubmission. Per the FDA guidelines, the review of a Class 2 resubmission is completed within six months of acceptance. The FDA's acceptance of the terlipressin NDA is yet to be announced.

Update on Lawsuit – Mar 16

Mallinckrodt received a decision from the U.S. District Court For The District Of Columbia in its suit against HHS and CMS (or the Agency) regarding the company's calculation of Medicaid drug rebates for Acthar. The District Court upheld CMS' decision to reverse its previous determination of the base date average manufacturer price (AMP) used to calculate Acthar Gel rebates. Mallinckrodt will pay roughly \$650 million as charges.

Potential Role for Inhaled Nitric Oxide to Treat COVID-19 – Mar 12

Mallinckrodt announced that it is currently evaluating the limited published evidence suggesting a potential role for inhaled nitric oxide ("iNO") as a supportive measure in treating those patients infected with coronavirus (SARS-CoV-2) and having associated pulmonary complications.

Valuation

Mallinckrodt's shares are down 11.2% in the year-to-date period and down 79.6% over the trailing 12-month period. Stocks in the Zacks sub-industry and the Zacks Medical sector are down 57.8% and 4.3% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry is down 53.4% while the sector is up 1.1%.

The stock is currently trading at 0.55X forward 12-month earnings per share, which compares to 4.13X for the Zacks sub-industry, 22.2X for the Zacks sector and 20.67X for the S&P 500 index.

Over the past five years, the stock has traded as high as 16.21X and as low as 0.17X, with a 5-year median of 4.27X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$3.25 price target reflects 0.60X forward 12-month earnings per share.

The table below shows summary valuation data for MNK

Valuation Multiples - MNK					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	0.55	4.13	22.2	20.67
	5-Year High	16.21	16.2	22.2	20.79
	5-Year Low	0.17	4.13	15.81	15.19
	5-Year Median	4.27	9.38	18.81	17.45
P/S F12M	Current	0.1	0.68	2.69	3.22
	5-Year High	3.87	4.35	3.84	3.44
	5-Year Low	0.03	0.68	2.24	2.54
	5-Year Median	1.03	1.91	2.96	3.02
P/B TTM	Current	0.13	0.56	3.7	3.74
	5-Year High	2.92	2.88	5.05	4.55
	5-Year Low	0.04	0.56	2.9	2.84
	5-Year Median	0.63	1.31	4.28	3.65

As of 05/14/2020

Valuation Multiples - MNK					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	0.64	8.07	19.72	18.11
	5-Year High	16.28	16.2	21.07	19.34
	5-Year Low	0.17	6.54	15.81	15.19
	5-Year Median	4.52	9.41	18.81	17.45
P/S F12M	Current	0.11	1.46	2.53	3.07
	5-Year High	3.67	4.35	3.84	3.44
	5-Year Low	0.03	1.19	2.25	2.54
	5-Year Median	1.06	1.92	2.96	3.01
P/B TTM	Current	0.16	1.2	3.48	3.69
	5-Year High	2.92	2.88	5.05	4.55
	5-Year Low	0.04	0.87	2.9	2.84
	5-Year Median	0.68	1.32	4.3	3.63

As of 04/09/2020

Industry Analysis Zacks Industry Rank: Top 7% (18 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Akorn, Inc. (AKRX)	Neutral	2
Bausch Health Cos Inc. (BHC)	Neutral	3
Endo International plc (ENDP)	Neutral	2
Mylan N.V. (MYL)	Neutral	3
Novartis AG (NVS)	Neutral	3
Pacira BioSciences, Inc. (PCRX)	Neutral	3
Dr. Reddys Laboratories Ltd (RDY)	Neutral	3
Teva Pharmaceutical Industries Ltd. (TEVA)	Neutral	2

Industry Comparison Industry: Medical - Generic Drugs				Industry Peers		
	MNK	X Industry	S&P 500	MYL	RDY	TEVA
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	2
VGM Score	A	-	-	A	A	A
Market Cap	249.99 M	300.49 M	18.95 B	7.87 B	8.35 B	11.98 B
# of Analysts	8	4	14	9	2	13
Dividend Yield	0.00%	0.00%	2.2%	0.00%	0.52%	0.00%
Value Score	A	-	-	A	C	A
Cash/Price	3.14	0.33	0.06	0.05	0.03	0.15
EV/EBITDA	-12.62	-3.08	11.58	7.25	15.60	75.82
PEG Ratio	0.04	0.69	2.60	1.27	NA	0.97
Price/Book (P/B)	0.13	2.56	2.59	0.70	4.01	0.82
Price/Cash Flow (P/CF)	0.15	2.82	10.20	1.83	18.67	2.82
P/E (F1)	0.52	6.24	19.00	3.53	28.14	4.54
Price/Sales (P/S)	0.08	2.70	1.93	0.68	3.43	0.69
Earnings Yield	199.66%	-15.46%	5.05%	28.38%	3.55%	22.06%
Debt/Equity	2.50	0.02	0.75	1.08	0.01	1.68
Cash Flow (\$/share)	20.20	-0.36	7.01	8.33	2.70	3.89
Growth Score	A	-	-	C	A	C
Hist. EPS Growth (3-5 yrs)	1.99%	1.99%	10.82%	2.42%	-0.76%	-19.38%
Proj. EPS Growth (F1/F0)	-33.50%	0.23%	-10.48%	-2.36%	19.33%	0.77%
Curr. Cash Flow Growth	10.71%	9.45%	5.68%	-3.91%	29.21%	-9.67%
Hist. Cash Flow Growth (3-5 yrs)	10.87%	6.38%	8.52%	16.74%	-0.91%	-6.21%
Current Ratio	1.46	2.80	1.27	1.26	1.81	1.05
Debt/Capital	71.43%	8.59%	44.25%	51.83%	0.81%	62.65%
Net Margin	-39.56%	-39.56%	10.54%	0.54%	9.62%	-4.73%
Return on Equity	29.14%	-44.13%	16.29%	20.00%	18.08%	18.10%
Sales/Assets	0.30	0.33	0.54	0.37	0.75	0.30
Proj. Sales Growth (F1/F0)	-16.59%	0.00%	-2.55%	4.05%	6.07%	-5.11%
Momentum Score	C	-	-	B	B	D
Daily Price Chg	0.00%	-2.06%	1.17%	-2.06%	0.96%	-0.72%
1 Week Price Chg	-8.41%	1.28%	3.23%	8.96%	3.62%	11.34%
4 Week Price Chg	-11.91%	7.43%	1.06%	-1.81%	-0.75%	5.89%
12 Week Price Chg	-42.64%	-11.99%	-22.80%	-27.26%	12.31%	-17.58%
52 Week Price Chg	-80.48%	-26.50%	-12.40%	-24.69%	25.58%	-3.94%
20 Day Average Volume	5,583,829	272,413	2,553,422	6,374,598	224,644	12,973,656
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	-0.05%	-1.38%	0.22%
(F1) EPS Est 4 week change	-3.42%	0.00%	-5.57%	-0.64%	-1.38%	0.17%
(F1) EPS Est 12 week change	-13.77%	-4.26%	-16.22%	-4.26%	-5.54%	-2.20%
(Q1) EPS Est Mthly Chg	-22.30%	0.00%	-11.63%	-2.12%	NA	-11.09%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	A
Momentum Score	C
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.